Literature DB >> 15851750

Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP.

M Iijima1, M Yamamoto, M Hirayama, F Tanaka, M Katsuno, K Mori, H Koike, N Hattori, K Arimura, M Nakagawa, H Yoshikawa, K Hayasaka, O Onodera, M Baba, H Yasuda, T Saito, M Nakazato, K Nakashima, J Kira, R Kaji, N Oka, G Sobue.   

Abstract

To identify clinical and electrophysiologic features related to IV immunoglobulin (IVIg) responsiveness in chronic inflammatory demyelinating polyneuropathy (CIDP), the authors conducted a multicenter study on 312 patients with CIDP (199 responders and 113 nonresponders). Muscle atrophy and decreased compound muscle action potential were pronounced in nonresponders of IVIg. Male gender, longer disease duration, and slow progression of symptoms were also associated with IVIg unresponsiveness. Features suggesting axonal dysfunction in peripheral nerves indicated IVIg unresponsiveness in CIDP.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15851750     DOI： 10.1212/01.WNL.0000158680.89323.F8

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  15 in total

Review 1.  [Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010].

Authors:  M Stangel; R Gold
Journal:  Nervenarzt       Date:  2011-04       Impact factor: 1.214

Review 2.  Diagnosis and treatment of chronic acquired demyelinating polyneuropathies.

Authors:  Norman Latov
Journal:  Nat Rev Neurol       Date:  2014-07-01       Impact factor: 42.937

Review 3.  Treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  Inna Kleyman; Thomas H Brannagan
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

4.  Early predictive factors of disability in CIDP.

Authors:  Emanuele Spina; Antonietta Topa; Rosa Iodice; Stefano Tozza; Lucia Ruggiero; Raffaele Dubbioso; Marcello Esposito; Dario Bruzzese; Lucio Santoro; Fiore Manganelli
Journal:  J Neurol       Date:  2017-08-02       Impact factor: 4.849

5.  An update on the management of chronic inflammatory demyelinating polyneuropathy.

Authors:  Kenneth C Gorson
Journal:  Ther Adv Neurol Disord       Date:  2012-11       Impact factor: 6.570

Review 6.  Initial and long-term management of autoimmune neuropathies.

Authors:  Carol Lee Koski
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 7.  New evidence for secondary axonal degeneration in demyelinating neuropathies.

Authors:  Kathryn R Moss; Taylor S Bopp; Anna E Johnson; Ahmet Höke
Journal:  Neurosci Lett       Date:  2020-12-24       Impact factor: 3.046

8.  Nerve ultrasound may help predicting response to immune treatment in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Jingwen Niu; Lei Zhang; Jing Fan; Jingwen Liu; Qingyun Ding; Yuzhou Guan; Shuang Wu; Liying Cui; Mingsheng Liu
Journal:  Neurol Sci       Date:  2022-01-21       Impact factor: 3.307

9.  Treatment Responsiveness in CIDP Patients with Diabetes Is Associated with Higher Degrees of Demyelination.

Authors:  Alon Abraham; Majed Alabdali; Mohammad Qrimli; Hana Albulaihe; Ari Breiner; Carolina Barnett; Hans D Katzberg; Leif E Lovblom; Bruce A Perkins; Vera Bril
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

10.  Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern.

Authors:  Filip Eftimov; Marinus H Liesdek; Camillus Verhamme; Ivo N van Schaik
Journal:  BMC Neurol       Date:  2014-04-04       Impact factor: 2.474
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.